Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Identification of a novel mutation of MEN1 gene in a patient with persisting primary hyperparathyroidism

ea0022p379 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

No secreting multiple glucagonoma: one case

ea0022p380 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

RET codon 618 mutations is the most frequent phenotype in Saudi families with multiple endocrine neoplasia type 2A

ea0022p381 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

CYP24A1 haplotypes are associated with differentiated thyroid carcinoma

ea0022p382 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Surgical treatment of insulinomas: a single-institution experience of 48 patients

ea0022p383 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Temozolomide treatment in aggressive pituitary tumors and pituitary carcinomas: a French multicenter experience

ea0022p384 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Real-time PCR is useful to detect menin gene deletions

ea0022p385 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Role of piuitary tumour transforming gene 1 in medullary thyroid carcinoma

ea0022p386 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Everolimus reduces human ACTH-secreting pituitary adenoma in vitro cell viability

ea0022p387 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

GH influences breast cancer chemoresistanec independently of cell cycle perturbations

ea0022p388 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Human presentation of MEN X syndrome

ea0022p389 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

The diagnostic value of PTH concentration in the needle washout after fine-needle biopsy of suspicious cervical foci in patients with hyperparathyroidism

ea0022p390 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Sex hormone-binding globulin (SHBG) gene pentanucleotide TAAAA repeat and D327N polymorphism in breast cancer: link to estrogen sensitivity

ea0022p391 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Anti-tumor activity of the tumor-vascular-disrupting agent ASA404 (vadimezan) in endocrine tumor models

ea0022p392 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Primary hyperparathyroidism and hyperuricaemia and bone turnover

ea0022p393 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Bilateral giant myelolipoma of adrenal glands: a case report and review of the literature

ea0022p394 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

A case of septo-optical dysplasia: are late complications inevitable in spite of early diagnosis and regular follow-up?

ea0022p395 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Rare metastases localization in medullary thyroid carcinoma (MTC)

ea0022p396 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Outcome of two chemotherapies in the treatment of progressive, undifferentiated neuroendocrine carcinomas: a single-center experience

ea0022p397 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Incidence, clinical presentation and outcome of differentiated thyroid cancer in young patients aged 10--24 years living in the French Rhone-Alpes region

ea0022p398 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Clinical, hormonal and molecular differences in pituitary ACTH adenomas without (silent corticotroph adenomas) or with Cushing's disease

ea0022p399 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Six members of a family with multiple endocrine neoplasia type 2A

ea0022p400 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Hepatic transplant and use of radionuclides as adyuvant therapies for patients with metastasic disease from neuroendocrine tumors

ea0022p401 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Down-regulation of estrogen receptor-β associates with transcriptional coregulator PATZ1 delocalization in human testicular seminomas

ea0022p402 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

High prevalence of dopamine excess in patients with head and neck paragangliomas

ea0022p403 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Pheochromocytoma: seconds from disaster

ea0022p404 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Ectopic insulin secretion from distant metastasis or ectopic metaplasia after total pancreatectomy for ACTH-secreting endocrine pancreatic tumor revealing a Von Hippel Lindau disease

ea0022p405 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Cinacalcet hydrochloride effectively controlled primary hyperparathyroidism in patients unresponsive to bisphosphonates

ea0022p406 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Clinical and prognostic implications of the genetic diagnosis of hereditary NET syndromes in asymptomatic patients

ea0022p407 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Expression of Ki-67, RET and p53 in papillary thyroid microcarcinomas with or without autoimmune thyroid diseases

ea0022p408 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Long-term outcome of 65 patients with metastatic differentiated thyroid carcinoma

ea0022p413 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Von Hippel-Lindau disease: a case report

ea0022p414 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Natural history and clinical features of metastatic differentiated thyroid carcinoma

ea0022p415 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Atypical bronchopulmonary carcinoid tumor metastatic to endocrine glands and bone marrow

ea0022p416 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma characterized for plasma mitotane level and ERCC1 protein expression analyses

ea0022p417 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Rapid activation of cPLA₂ induced by oestrogen in ER-positive and ER-negative breast cancer cell lines

ea0022p418 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Adrenocortical carcinoma: is the surgical approach a risk factor of peritoneal carcinomatosis?

ea0022p419 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Erythropoietin levels in endocrinopathies

ea0022p420 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Prolactinoma registry- usefulness of a web tool

ea0022p421 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Thyroid Incidentaloma identified by ¹⁸F-Fluorodeoxyglucose Positron Emission Tomography with CT (FDG-PET/CT): clinical relevance

ea0022p422 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Juvenile hypertension due to coexistence of two very rare etiologies

ea0022p423 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Reversible heart failure after sorafenib administration in advanced metastatic differentiated thyroid carcinoma (DTC)

ea0022p424 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Serum concentration of o,p’DDD (mitotane), o,p’DDA and o,p’DDE as predictors of tumour response in adrenocortical carcinoma: results of a retrospective European Network for the Study of Adrenal Tumors (ENS@T) multicentre study

ea0022p425 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Clinical features and outcome of sporadic medullary thyroid carcinoma

ea0022p426 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Adrenocortical carcinoma (ACC): our experience

ea0022p427 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Polymorphisms in RET gene are associated with RET/PTC rearrangements in papillary thyroid carcinoma (PTC)

ea0022p428 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Malignant paraganglioma – the story of a long time survival

ea0022p429 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Ectopic Cushing’s syndrome caused by a well differentiated ACTH-secreting neuroendocrine carcinoma of the ileum

ea0022p430 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Intronic polymorphism IVS14-24G/A of the RET proto-oncogene seems to be protective for sporadic medullary thyroid carcinoma development

ea0022p431 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

The Role of miRNA in reduction of type I 5’-iodothyronine deiodinase expression (D1) in renal clear cell carcinoma (ccRCC)

ea0022p432 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Unexplained hypoxemia in a patient with carcinoid syndrome

ea0022p433 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Pituitary adenoma mimicking a psychiatric disorder – a case report

ea0022p434 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Identification of hyperfunctioning parathyroids (HP) in primary hyperparathyroidism (pHPT) in the presence of concomitant thyroid diseases

ea0022p435 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Molecular analysis of tumor tissue enabled selection of a successful combined therapy of somatostatin and dopamine agonists in a case of TSH-secreting pituitary adenoma

ea0022p436 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Aryl hydrocarbon receptor- interacting protein: mutational analysis and functional validation in primary pituitary cell cultures

ea0022p437 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

RET mutation screening in multiple endocrine neoplasia type 2 (MEN2) and medullary thyroid carcinoma patients (MTC) in Romania

ea0022p438 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Gonadotrophinoma and parathyroid adenoma

ea0022p439 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Cushing’s syndrome, clinicaly non-functioning pituitary adenoma and hypercalcemia

ea0022p440 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Use of recombinant human thyroid-stimulating hormone (rhTSH) in children and adolescents with differentiated thyroid cancer

ea0022p441 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Metastatic mammary carcinomas with neuroendocrine features- a case report

ea0022p442 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

The laterocervical unique masses – a challenging pathology

ea0022p443 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Is In2-ghrelin variant, a ghrelin gene derived transcript, a novel player in breast cancer tumors?

ea0022p444 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Gastroenteropatic Neuroendocrine tumors: multidisciplinary approach in therapy

ea0022p445 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

The use of receptor tyrosine kinase inhibitors in metastatic differentiated thyroid carcinoma

ea0022p446 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

The relationship of testosterone to PSA in men with sexual dysfunction

ea0022p447 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Primary carcinoid as an incidental finding in a mature cystic teratoma of the ovary: case report

ea0022p448 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Conditions and implications of rhTSH application for ablation in treatment of Differentiated thyroid cancer

ea0022p449 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Pheochromocytomas in the RET protooncogene mutations carriers

ea0022p450 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Unusual cause of hyercalcemia in pheochromocytoma

ea0022p451 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Prokineticin 1 stimulates prostate epithelial cell migration and proliferation in vitro

ea0022p452 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Cushing’s disease as the first manifestation of familial multiple endocrine neoplasia syndrome type 1

ea0022p453 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Two exceptional etiologies of classic endocrinopathies

ea0022p454 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Peptide receptor radionuclide therapy and NETs: how to select patients?

ea0022p455 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

Clinical characteristics of incidentally discovered phaeochromocytomas

ea0022p456 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

The clonidine supression test with measurement of plasma metanephrines by enzyme immunoassay

ea0022p457 | Endocrine tumours & neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

12th European Congress of Endocrinology

Endocrine tumours &amp; neoplasia (<emphasis role="italic">Generously supported by Novartis</emphasis>)

BiosciAbstracts